Le Lézard
Classified in: Health
Subjects: CCA, BFA, PET, FVT

Aratana Therapeutics to Report Third Quarter 2017 Financial Results


LEAWOOD, Kan., Oct. 5, 2017 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, will host a live conference call on Friday, November 3, 2017 at 8:30 a.m. ET to discuss financial results from the third quarter ended September 30, 2017.

Aratana Therapeutics logo

Interested participants and investors may access the audio webcast or use the conference call dial-in:

     1 (866) 364-3820 (U.S.) 
     1 (855) 669-9657 (Canada)
     1 (412) 902-4210 (International)

A replay of the third quarter results teleconference will be available the same day of the event by approximately 11 a.m. ET and an audio webcast will be accessible for 90 days in the Aratana Investor Room. For a replay of the call, use the below dial-in and conference ID 10112622:

     1 (877) 344-7529 (U.S.) 
     1 (855) 669-9658 (Canada
     1 (412) 317-0088 (International)

About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative therapeutics for dogs and cats. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to dogs and cats in a capital and time efficient manner. The company's pipeline includes therapeutic candidates for the potential treatment of pain, inappetence, viral diseases, allergy, cancer and other serious medical conditions. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit www.aratana.com.

Contacts
For investor inquires:
Craig Tooman
[email protected] 
(913) 353-1026

For media inquiries:
Rachel Reiff
[email protected] 
(913) 353-1050

SOURCE Aratana Therapeutics, Inc.


These press releases may also interest you

at 09:15
n-Lorem, a nonprofit foundation, announced a new partnership with Hongene Biotech Corporation that supports n-Lorem's efforts to discover and provide personalized experimental antisense oligonucleotide (ASO) medicines to nano-rare disease patients (1...

at 09:11
For over 30 years Protocall's behavioral health contact center, HelpNow, has set industry standards for round-the-clock access to high-quality crisis care. Received calls are documented within Protocall's custom database and sent to the caller's care...

at 09:10
Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the launch of a Phase II clinical study in minimal residual disease positive (MRD+) HPV-driven head and neck cancer. The study will be led by...

at 09:06
Memora Health, the leading intelligent care enablement platform, today announced an expansion of its leadership team with the addition of Divya Bhat as Chief Product Officer and Herman Ng as Chief Financial Officer. Divya and Herman bring unique...

at 09:05
Quantum Health, the leading consumer healthcare navigation and care coordination company, announced today the launch of its new end-to-end care management solution, Premier Oncology, tailored for employers and their members diagnosed with cancer....

at 09:05
United Therapeutics Corporation , a public benefit corporation, today announced the world's first successful transplant of a UThymoKidneytm, which the company produced, into a living person on April 12, 2024. This transplant represents several...



News published on and distributed by: